PLX-61639 / Plexium - LARVOL DELTA

PLX-61639, a potent and orally bioavailable SMARCA2-selective monovalent direct degrader, enhances efficacy of standard of care agents in SMARCA4 mutant tumor models (AACR 2026) - "PLX-61639 demonstrates robust combination benefit with multiple standard of care agents utilizing different modalities, suggesting potential effective treatment options for future development. The results disclosed here highlight the development of PLX-61639, a potent and selective SMARCA2 monovalent direct degrader, and demonstrate its utility in the treatment of SMARCA4MUT solid tumors."

Preclinical • Oncology • Solid Tumor • SMARCA2 • SMARCA4

A Phase 1, first-in-human study of the SMARCA2 degrader, PLX-61639, in patients with SMARCA4-mutated, locally advanced or metastatic solid tumors (AACR 2026) - "Abstract is embargoed at this time."

Clinical • First-in-human • Metastases • P1 data • Oncology • Solid Tumor • SMARCA2 • SMARCA4

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=155 | Recruiting | Sponsor: Plexium, Inc.

First-in-human • New P1 trial • Esophageal Adenocarcinoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Esophagogastric Junction Squamous Cell Carcinoma • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

Plexium Announces Multiple Presentations at AACR 2025 with Selective Monovalent Degrader Programs Targeting SMARCA2…and CDK2 (PRNewswire) - "Plexium...announced today multiple presentations with the Company's selective monovalent degrader programs for SMARCA2...and CDK2 at the 2025 American Association for Cancer Research (AACR) Annual Meeting....PLX-61639, a selective, oral SMARCA2 degrader, demonstrated sustained PD response and single-agent efficacy in SMARCA4 mutant tumors; program is advancing through IND-enabling studies....Preclinical data was presented on its CDK2 selective molecular glue degrader, which exhibited superior selectivity over inhibitor-based approaches; program is targeting CCNE1 amplified cancers."

Preclinical • Oncology

Preclinical characterization of PLX-61639, a potent and orally bioavailable SMARCA2-selective monovalent direct degrader (AACR 2025) - "These results highlight the efficient discovery and development of potent and selective SMARCA2 monovalent direct degraders. Further, the preclinical characterization of our development candidate, PLX-61639, demonstrates its activity and potential utility in the treatment of SMARCA4MUT solid tumors."

Preclinical • Oncology • Solid Tumor • SMARCA2 • SMARCA4

Plexium Announces Two Oral Presentations and Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 (PRNewswire) - "Plexium...announced that initial Phase 1 clinical results with PLX-4545, a selective IKZF2 molecular glue degrader, and preclinical results from the Company's SMARCA2 monovalent direct degrader and CDK2 molecular glue degrader programs will be presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting..."

P1 data • Preclinical • Oncology